These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 28144724)

  • 1. Pharmacokinetics of a new, nasal formulation of naloxone.
    Tylleskar I; Skulberg AK; Nilsen T; Skarra S; Jansook P; Dale O
    Eur J Clin Pharmacol; 2017 May; 73(5):555-562. PubMed ID: 28144724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of concentrated naloxone nasal spray over first 30 minutes post-dosing: analysis of suitability for opioid overdose reversal.
    Mundin G; McDonald R; Smith K; Harris S; Strang J
    Addiction; 2017 Sep; 112(9):1647-1652. PubMed ID: 28430384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics after a single dose of naloxone administered as a nasal spray in healthy volunteers.
    Vanky E; Hellmundt L; Bondesson U; Eksborg S; Lundeberg S
    Acta Anaesthesiol Scand; 2017 Jul; 61(6):636-640. PubMed ID: 28444856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: Phase I healthy volunteer study.
    McDonald R; Lorch U; Woodward J; Bosse B; Dooner H; Mundin G; Smith K; Strang J
    Addiction; 2018 Mar; 113(3):484-493. PubMed ID: 29143400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioavailability investigation of a new tilidine/naloxone liquid formulation compared to a reference formulation.
    Martin W; Ring J; Gaupp M; Arnold P; Sennewald R; Doser K
    Arzneimittelforschung; 1999 Jul; 49(7):599-607. PubMed ID: 10442208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Naloxone nasal spray - bioavailability and absorption pattern in a phase 1 study.
    Tylleskar I; Skulberg AK; Nilsen T; Skarra S; Dale O
    Tidsskr Nor Laegeforen; 2019 Sep; 139(13):. PubMed ID: 31556537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and -dynamics of intramuscular and intranasal naloxone: an explorative study in healthy volunteers.
    Skulberg AK; Tylleskar I; Nilsen T; Skarra S; Salvesen Ø; Sand T; Loftsson T; Dale O
    Eur J Clin Pharmacol; 2018 Jul; 74(7):873-883. PubMed ID: 29568976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of a novel, approved, 1.4-mg intranasal naloxone formulation for reversal of opioid overdose-a randomized controlled trial.
    Skulberg AK; Åsberg A; Khiabani HZ; Røstad H; Tylleskar I; Dale O
    Addiction; 2019 May; 114(5):859-867. PubMed ID: 30644628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the Pharmacokinetic Properties of Naloxone Following the Use of FDA-Approved Intranasal and Intramuscular Devices Versus a Common Improvised Nasal Naloxone Device.
    Krieter PA; Chiang CN; Gyaw S; McCann DJ
    J Clin Pharmacol; 2019 Aug; 59(8):1078-1084. PubMed ID: 30861160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic Properties and Human Use Characteristics of an FDA-Approved Intranasal Naloxone Product for the Treatment of Opioid Overdose.
    Krieter P; Chiang N; Gyaw S; Skolnick P; Crystal R; Keegan F; Aker J; Beck M; Harris J
    J Clin Pharmacol; 2016 Oct; 56(10):1243-53. PubMed ID: 27145977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics of intravenous, intramuscular, and intranasal naloxone in human volunteers.
    Dowling J; Isbister GK; Kirkpatrick CM; Naidoo D; Graudins A
    Ther Drug Monit; 2008 Aug; 30(4):490-6. PubMed ID: 18641540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pharmacokinetic interaction between nasally administered naloxone and the opioid remifentanil in human volunteers.
    Tylleskar I; Skarra S; Skulberg AK; Dale O
    Eur J Clin Pharmacol; 2021 Dec; 77(12):1901-1908. PubMed ID: 34327552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Novel Faster-Acting, Dry Powder-Based, Naloxone Intranasal Formulation for Opioid Overdose.
    Lapidot T; Bouhajib M; Faulknor J; Khan S; Krayz GT; Abrutzky C; Megiddo D
    Pharm Res; 2022 May; 39(5):963-975. PubMed ID: 35386013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. International patent applications for non-injectable naloxone for opioid overdose reversal: Exploratory search and retrieve analysis of the PatentScope database.
    McDonald R; Danielsson Glende Ø; Dale O; Strang J
    Drug Alcohol Rev; 2018 Feb; 37(2):205-215. PubMed ID: 28597483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers.
    Middleton LS; Nuzzo PA; Lofwall MR; Moody DE; Walsh SL
    Addiction; 2011 Aug; 106(8):1460-73. PubMed ID: 21395892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic Interaction between Naloxone and Naltrexone Following Intranasal Administration to Healthy Subjects.
    Krieter P; Chiang CN; Gyaw S; Skolnick P; Snyder R
    Drug Metab Dispos; 2019 Jul; 47(7):690-698. PubMed ID: 30992306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical provision of improvised nasal naloxone without experimental testing and without regulatory approval: imaginative shortcut or dangerous bypass of essential safety procedures?
    Strang J; McDonald R; Tas B; Day E
    Addiction; 2016 Apr; 111(4):574-82. PubMed ID: 26840916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of naloxone nasal spray 4 mg in the community setting: a survey of use by community organizations.
    Avetian GK; Fiuty P; Mazzella S; Koppa D; Heye V; Hebbar P
    Curr Med Res Opin; 2018 Apr; 34(4):573-576. PubMed ID: 28535115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of a high-dose target-controlled naloxone infusion on pain and hyperalgesia in patients following groin hernia repair: study protocol for a randomized controlled trial.
    Pereira MP; Werner MU; Dahl JB
    Trials; 2015 Nov; 16():511. PubMed ID: 26554360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and pharmacodynamics of intranasal and intravenous naloxone hydrochloride administration in healthy dogs.
    Wahler BM; Lerche P; Ricco Pereira CH; Bednarski RM; KuKanich B; Lakritz J; Aarnes TK
    Am J Vet Res; 2019 Jul; 80(7):696-701. PubMed ID: 31246123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.